Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Medilux is a South Korean biotechnology company specializing in the development of innovative light-responsive drug delivery systems. The company's proprietary platform, Light-Induced Drug Delivery System (LIDDS), utilizes specific wavelengths of light to trigger the precise release of therapeutic agents at targeted sites, such as solid tumors or ocular tissues. This spatiotemporal control aims to maximize therapeutic efficacy while significantly reducing systemic side effects associated with conventional treatments. Medilux is currently advancing a pipeline of nanomedicines, with lead programs focused on oncology and ophthalmology, including treatments for age-related macular degeneration. By combining advanced materials science with photomedicine, the company seeks to provide next-generation solutions for localized and difficult-to-treat diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medilux.